Abdulla Taja, MD
Gastroenterology · Lima, OHNPI 1811954142
Payments from drug & device makers
Across 206 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$839
- AbbVie$546
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$525
- Sanofi$289
- Madrigal Pharmaceuticals$147
- Phathom Pharmaceuticals, Inc.$120
- plus $932 from 25 others
What the payments were for
- Food & beverage$3,34398%
- Education$552%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 48 | $839 |
| AbbVie(2 entities) | 37 | $546 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 40 | $525 |
| Sanofi | 12 | $289 |
| Madrigal Pharmaceuticals | 7 | $147 |
| Phathom Pharmaceuticals, Inc. | 7 | $120 |
| Johnson & Johnson | 6 | $114 |
| Merck | 4 | $75 |
| Daiichi Sankyo Inc. | 4 | $70 |
| Regeneron Healthcare Solutions, Inc. | 3 | $70 |
| Ardelyx, Inc. | 3 | $67 |
| Ironwood Pharmaceuticals, Inc | 5 | $66 |
| Aimmune Therapeutics, Inc. | 3 | $60 |
| Bristol Myers Squibb | 4 | $59 |
| Celltrion USA Inc. | 2 | $33 |
| Boehringer Ingelheim | 2 | $30 |
| Intercept Pharmaceuticals, Inc. | 2 | $28 |
| Gilead | 2 | $28 |
| Shionogi Inc | 2 | $26 |
| Nestle Healthcare Nutrition Inc. | 2 | $25 |
| Romark Laboratories, LC | 1 | $20 |
| Echosens North America, Inc. | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Pharmacosmos Therapeutics Inc. | 1 | $14 |
| QOL Medical, LLC | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $13 |
How this compares
$3,398 in reported general payments places this provider in the 55th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PentasaMesalamine | 15 | $5,517 |
| Ursodiol | 18 | $2,734 |
| Mesalamine | 14 | $2,286 |
| Omeprazole | 194 | $1,321 |
| Pantoprazole Sodium | 99 | $1,117 |
| Sucralfate | 32 | $996 |
| LoperamideLoperamide Hcl | 17 | $410 |
| Ondansetron Hcl | 14 | $323 |
| Famotidine | 42 | $305 |
| Sulfasalazine | 14 | $181 |
| Dicyclomine Hcl | 12 | $162 |
| Nystatin | 17 | $148 |
| Spironolactone | 12 | $57 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Lima
- Naim AlkhouriWestlake$10.1M
- Florian RiederCleveland$8.7M
- Keith FriedenbergMentor$5M
- Anita AfzaliCincinnati$2.4M
- Pierre GholamCleveland$1.9M
- Benjamin CohenCleveland$1.9M
- Mohamed NaemWestlake$1.6M
- Mousab TabbaaWestlake$1.4M
- Pradeep BekalCincinnati$1.4M
- Na LiColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.